Sanofi SA announced a 6% increase in Q2 net sales to €10 billion, with a 253% surge in net income under IFRS to €4 billion. CEO Paul Hudson updates 2025 sales guidance, reflecting ...
Sanofi is set to acquire UK vaccine firm Vicebio for up to $1.6 billion, aiming to expand its respiratory virus vaccine pipeline with Vicebio's 'Molecular Clamp' technology and a p...
Sanofi SA announces a $20 billion investment in the US by 2030 to expand manufacturing and R&D, aiming to secure medicine production and foster healthcare innovation.
Sanofi SA reports a 10.8% increase in Q1 net sales to €9.9 billion, with significant growth in net income and EPS. CEO Paul Hudson reaffirms the company's 2025 guidance, showcasing...
Sanofi SA announced a 10.8% increase in Q1 net sales to €9.9 billion, with notable growth in net income and EPS. CEO Paul Hudson reaffirmed the company's 2025 outlook, highlighting...
Sanofi SA reports a 10.8% annual increase in Q1 2025 net sales to €9.9 billion, with significant growth in net income and EPS, reaffirming its positive outlook for 2025.
Sanofi SA reports a 10.8% increase in Q1 2025 net sales to €9.9 billion, with significant growth in net income and EPS, affirming its 2025 financial guidance.
Sanofi S.A. plans a €3 billion share buyback from L'Oreal S.A., acquiring 29,556,650 shares at a 2.8% discount. This move reduces L'Oreal's stake to 7.2%, highlighting Sanofi's ded...
Sanofi S.A. has announced a €3 billion share buyback from L'Oreal S.A., acquiring 29,556,650 shares at €101.50 each. This move reinforces their strategic partnership and commitment...
Sanofi S.A. has announced a €3 billion share buyback from L'Oreal S.A., acquiring 2.3% of its shares at a discount. This strategic move strengthens their long-standing partnership,...
